Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

Summary

The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. This study was originally registered as NCT00067119 which included two protocols, this one and the GRAFT study)

Conditions

• Kidney Failure
• Hemodialysis Fistula Thrombosis

Interventions

DRUG

Clopidogrel

DRUG

Placebo

Sponsors & Collaborators

• The Cleveland Clinic

  collaborator OTHER

• Boston University

  collaborator OTHER

• Duke University

  collaborator OTHER

• University of Iowa

  collaborator OTHER

• MaineHealth

  collaborator OTHER

• University of Texas Southwestern Medical Center

  collaborator OTHER

• University of Alabama at Birmingham

  collaborator OTHER

• Washington University School of Medicine

  collaborator OTHER

• Baystate Medical Center

  collaborator OTHER

• Vanderbilt University

  collaborator OTHER

• CAMC Health System

  collaborator OTHER

• Emory University

  collaborator OTHER

• St. Louis University

  collaborator OTHER

• Tyler Nephrology Associates

  collaborator UNKNOWN

• Vascular Surgery Associates LLC

  collaborator OTHER

• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  lead NIH

Principal Investigators

• John W Kusek, Ph.D. · NIDDK - Telephone: 301-594-7717; Email: [email protected]

• Catherine Meyers, M.D. · NIDDK - Telephone: 301-451-4901; Email: [email protected]

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2003-01-07

Primary Completion

2007-06-18

Completion

2007-06-18

FDA Drug

Yes

Countries

• United States

Study Locations